Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: APD PPG DD ADM FMC DSM TSE ANDE FUTU RKT

| Held by: VTI VOO VO IVV SPY VTV RSP XLB VOE VYM

Index	S&P 500	P/E	-	EPS (ttm)	-1.37	Insider Own	1.81%	Shs Outstand	255.70M	Perf Week	6.59%
Market Cap	18.14B	Forward P/E	14.78	EPS next Y	4.80	Insider Trans	3.90%	Shs Float	250.85M	Perf Month	-12.27%
Enterprise Value	24.23B	PEG	1.92	EPS next Q	1.08	Inst Own	99.78%	Short Float	3.32%	Perf Quarter	6.11%
Income	-348.00M	P/S	1.67	EPS this Y	5.73%	Inst Trans	3.56%	Short Ratio	4.63	Perf Half Y	17.76%
Sales	10.89B	P/B	1.28	EPS next Y	8.20%	ROA	-1.28%	Short Interest	8.32M	Perf YTD	5.37%
Book/sh	55.35	P/C	30.75	EPS next 5Y	7.70%	ROE	-2.48%	52W High	84.45 -15.91%	Perf Year	-9.17%
Cash/sh	2.31	P/FCF	71.42	EPS past 3/5Y	42.26% -	ROIC	-1.79%	52W Low	59.14 20.07%	Perf 3Y	-20.77%
Dividend Est.	1.68 (2.37%)	EV/EBITDA	11.97	Sales past 3/5Y	-4.34% 16.46%	Gross Margin	30.96%	Volatility	2.83% 3.35%	Perf 5Y	-49.47%
Dividend TTM	1.60 (2.25%)	EV/Sales	2.23	EPS Y/Y TTM	-242.69%	Oper. Margin	9.76%	ATR (14)	2.40	Perf 10Y	-37.29%
Dividend Ex-Date	Mar 20, 2026	Quick Ratio	0.82	Sales Y/Y TTM	-5.17%	Profit Margin	-3.20%	RSI (14)	46.13	Recom	1.71
Dividend Gr. 3/5Y	-20.63% -12.05%	Current Ratio	1.42	EPS Q/Q	138.95%	SMA20	-1.03%	Beta	1.04	Target Price	91.50
Payout	168.56%	Debt/Eq	0.47	Sales Q/Q	-6.57%	SMA50	-4.45%	Rel Volume	1.13	Prev Close	71.15
Employees	21500	LT Debt/Eq	0.37	Earnings	Feb 11 AMC	SMA200	2.53%	Avg Volume	1.80M	Price	71.01
IPO	Mar 02, 1964	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.32% 3.00%	Trades		Volume	2,033,080	Change	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-26	Upgrade	Oppenheimer	Perform → Outperform	$97
Sep-08-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Aug-07-25	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-25	Initiated	Tigress Financial	Buy	$105
May-08-25	Upgrade	Barclays	Equal Weight → Overweight	$84
Feb-20-25	Downgrade	CFRA	Buy → Sell	$77
Jan-07-25	Upgrade	Argus	Hold → Buy
Nov-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$111 → $110
Nov-08-24	Upgrade	BofA Securities	Neutral → Buy	$107
Nov-07-24	Upgrade	Vertical Research	Hold → Buy	$109
Sep-11-24	Reiterated	Oppenheimer	Outperform	$116 → $117
Sep-03-24	Upgrade	Mizuho	Neutral → Outperform	$109 → $120
Jul-22-24	Upgrade	Stifel	Hold → Buy	$95 → $115
Jun-07-24	Initiated	Oppenheimer	Outperform	$116
May-21-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$100
May-08-24	Upgrade	JP Morgan	Neutral → Overweight	$75 → $100
Apr-18-24	Upgrade	Barclays	Underweight → Equal Weight
Apr-10-24	Upgrade	Citigroup	Neutral → Buy	$81 → $100
Mar-08-24	Downgrade	Argus	Buy → Hold
Mar-01-24	Initiated	Wolfe Research	Underperform

Show Previous Ratings

Mar-13-26 07:53AM	Is International Flavors & Fragrances Stock Underperforming the S&P 500? (Barchart)
Mar-11-26 08:49AM	Is DuPont de Nemours Stock Outperforming the S&P 500? (Barchart) -5.67%
Mar-10-26 04:30PM	IFF Expands Latin American Footprint With New Enzyme Hub, Brazil Application Lab (Business Wire)
Mar-06-26 07:26PM	Analyst Report: International Flavors & Fragrances Inc. (Morningstar Research)
Mar-04-26 10:39PM	Winners And Losers Of Q4: International Flavors & Fragrances (NYSE:IFF) Vs The Rest Of The Ingredients, Flavors & Fragrances Stocks (StockStory)
04:15PM	Loading…
04:15PM	IFF Declares Dividend for First Quarter 2026 (Business Wire)
Mar-03-26 10:22AM	Jim Cramer on International Flavors & Fragrances: "We Think That the Turnabout Is Real" (Insider Monkey)
Mar-02-26 11:08PM	3 Reasons IFF is Risky and 1 Stock to Buy Instead (StockStory)
04:15PM	IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses (Business Wire)
Feb-24-26 08:15AM	LMR Unveils Tonka Bean CO2 Absolute: Gourmand Excellence from Planet-Friendly Extraction (Business Wire)
Feb-20-26 12:37PM	International Flavors & Fragrances Inc.'s (IFF) Q4 Results Ease Concerns About European Slowdown, Says BofA (Insider Monkey)
Feb-18-26 12:37AM	5 Revealing Analyst Questions From International Flavors & Fragrances's Q4 Earnings Call (StockStory)
Feb-13-26 09:09PM	Analyst Report: International Flavors & Fragrances Inc. (Morningstar Research)
12:07AM	International Flavors & Fragrances Q4 Earnings Call Highlights (MarketBeat)
Feb-12-26 04:03PM	International Flavors & Fragrances Inc (IFF) Q4 2025 Earnings Call Highlights: Strong ... (GuruFocus.com) +5.89%
12:21PM	Loading…
12:21PM	International Flavors Q4 Earnings Miss Estimates, Sales Dip Y/Y (Zacks) +5.89%
10:45AM	Is Wall Street Bullish or Bearish on International Flavors & Fragrances Stock? (Barchart) +5.89%
08:30AM	International Flavors & Fragrances Inc. Q4 2025 Earnings Call Summary (Moby) +5.89%
Feb-11-26 06:00PM	International Flavors (IFF) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:25PM	International Flavors (IFF) Q4 Earnings Miss Estimates (Zacks) +5.89%
04:48PM	International Flavors & Fragrances's (NYSE:IFF) Q4 CY2025 Sales Top Estimates (StockStory) +5.89%
04:35PM	International Flavors: Q4 Earnings Snapshot (Associated Press Finance) +5.89%
04:15PM	IFF Reports Fourth Quarter and Full Year 2025 Results (Business Wire) +5.89%
Feb-09-26 10:01PM	International Flavors & Fragrances (IFF) Q4 Earnings Report Preview: What To Look For (StockStory)
10:11AM	International Flavors to Report Q4 Earnings: What's in Store? (Zacks)
Feb-06-26 09:15AM	International Flavors (IFF) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Feb-05-26 08:40AM	Green Plains Renewable Energy (GPRE) Q4 Earnings Surpass Estimates (Zacks)
Feb-04-26 10:00AM	International Flavors (IFF) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks) +5.56%
Feb-02-26 08:15AM	Tastepoint by IFF Predicts Ten Flavor Trends for 2026 (Business Wire)
Jan-29-26 11:02PM	International Flavors & Fragrances (IFF): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
11:04PM	Loading…
Jan-27-26 11:04PM	3 Reasons IFF is Risky and 1 Stock to Buy Instead (StockStory)
Jan-23-26 09:35AM	IFF price target raised to $80 from $70 at Argus (TipRanks)
09:02AM	Potential Rate Cuts to Drive Momentum for International Flavors & Fragrances (IFF) (Insider Monkey)
Jan-21-26 04:15PM	IFF to Release Fourth Quarter & Full Year 2025 Results on Feb. 11, 2026; IFF to Present at 2026 CAGNY Conference on Feb. 19, 2026 (Business Wire)
Jan-18-26 11:03PM	3 Reasons to Avoid IFF and 1 Stock to Buy Instead (StockStory)
Jan-16-26 05:28AM	International Flavors & Fragrances Quarterly Earnings Preview: What You Need to Know (Barchart)
Jan-15-26 10:35PM	Q3 Earnings Roundup: International Flavors & Fragrances (NYSE:IFF) And The Rest Of The Ingredients, Flavors & Fragrances Segment (StockStory)
Jan-14-26 11:04PM	3 Reasons to Avoid IFF and 1 Stock to Buy Instead (StockStory)
Dec-31-25 10:39AM	IFF Gains From Focus on Growth Despite Low Food Ingredient Volumes (Zacks)
Dec-30-25 12:48PM	International Flavors & Fragrances (NYSE:IFF) Surprises With Q3 CY2025 Sales (StockStory)
Dec-23-25 10:02AM	Implied Volatility Surging for International Flavors Stock Options (Zacks)
Dec-10-25 03:20PM	Analyst Report: International Flavors & Fragrances Inc. (Morningstar Research)
Dec-09-25 10:17AM	How Is International Flavors & Fragrances' Stock Performance Compared to Other Material Stocks? (Barchart)
Dec-04-25 11:30AM	International Flavors (IFF) Up 4.9% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-24-25 04:05PM	Mativ Announces Appointment of Seasoned Executive to Its Board of Directors (Business Wire)
Nov-23-25 08:00PM	IFF Introduces Smart Dosing Robot to Transform Fragrance Production (Business Wire)
Nov-21-25 09:22AM	Implied Volatility Surging for International Flavors Stock Options (Zacks)
Nov-17-25 09:15AM	International Markets and International Flavors (IFF): A Deep Dive for Investors (Zacks)
Nov-13-25 11:35PM	Are Wall Street Analysts Bullish on International Flavors & Fragrances Stock? (Barchart)
Nov-06-25 08:17AM	Do You Believe in the Upside Potential of International Flavors & Fragrances (IFF)? (Insider Monkey)
03:00AM	IFF Benicarlo Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing (Business Wire)
03:00AM	IFF Benicarl Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing (Business Wire)
Nov-05-25 04:05PM	International Flavors & Fragrances Inc (IFF) Q3 2025 Earnings Call Highlights: Strong ... (GuruFocus.com)
01:11PM	International Flavors Earnings Beat Estimates in Q3, Sales Dip Y/Y (Zacks)
12:50PM	Analyst Report: International Flavors & Fragrances Inc. (Morningstar Research)
Nov-04-25 10:37PM	Wall Street gains ground amid steady flow of earnings reports, upbeat economic updates (Associated Press)
06:00PM	International Flavors (IFF) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	International Flavors (IFF) Q3 Earnings and Revenues Top Estimates (Zacks)
04:24PM	International Flavors: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	IFF Reports Third Quarter 2025 Results (Business Wire)
Nov-03-25 01:11PM	Hecla Mining to Report Q3 Results: What's in the Cards for the Stock? (Zacks)
11:50AM	B2Gold Gets Ready to Report Q3 Earnings: Here's What to Expect (Zacks)
Oct-31-25 01:14PM	SSR Mining is Set to Report Q3 Earnings: Here's What to Expect (Zacks)
Oct-30-25 06:35PM	Quaker Chemical (KWR) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:15PM	IFF Declares Dividend for Fourth Quarter 2025 (Business Wire)
06:00AM	IFF Honors Distinguished Academics Shaping the Future of Nutrition, Health and Biosciences (Business Wire)
Oct-29-25 02:14PM	International Flavors to Report Q3 Earnings: What's in the Offing? (Zacks)
Oct-28-25 10:00AM	International Flavors (IFF) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
09:10AM	Ecolab (ECL) Q3 Earnings and Revenues Beat Estimates (Zacks)
Oct-22-25 04:15PM	IFF Announces Appointment of Brett Icahn and Richard Mulligan to Board of Directors (Business Wire)
Oct-21-25 06:00AM	IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation (Business Wire)
Oct-17-25 03:48PM	Most Chemical Stocks Look Corrosive. These 3 Might Be Buys. (Barrons.com)
06:40AM	International Flavors & Fragrances Q3 2025 Earnings: What to Expect (Barchart)
Oct-15-25 12:10PM	Will International Flavors (IFF) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-14-25 04:15PM	IFF to Release Third Quarter 2025 Results on Nov. 4, 2025 (Business Wire)
Oct-11-25 10:03AM	Jim Cramer on International Flavors & Fragrances: It Used to Be a Better Company (Insider Monkey)
Oct-08-25 10:30PM	IFF Plans New Scent Creative Center in Mumbai, India (Business Wire)
Oct-03-25 06:27AM	What Do Analysts Think About International Flavors & Fragrances (IFF)? (Insider Monkey)
04:47AM	International Flavors & Fragrances Inc. (IFF) Unveils SipScape to Enhance Brand Awareness (Insider Monkey)
Oct-01-25 04:30PM	IFF secures ISO/IEC 27001 certification, elevating global trust in data security and operational excellence (Business Wire)
Sep-17-25 08:52AM	International Flavors & Fragrances Stock: Is IFF Underperforming the Materials Sector? (Barchart)
Sep-14-25 01:17AM	Wolfe Research Upgrades International Flavors & Fragrances (IFF) to Peer Perform From Underperform (Insider Monkey)
Sep-10-25 05:21AM	FORA Capital Raises Bet on International Flavors & Fragrances Inc. (IFF)'s 2026 Turnaround (Insider Monkey)
Sep-09-25 07:00AM	IFF launches interactive platform to inspire adult beverage innovation (Business Wire)
Sep-08-25 12:07PM	International Flavors' DEB Platform Announces Commercial Debut (Zacks)
05:00AM	IFF expands LMR Naturals site in Grasse, advancing naturals innovation leadership (Business Wire)
Sep-04-25 07:00AM	IFF's Designed Enzymatic Biomaterials Platform Sees First Large-Scale Use in Home Care Applications (Business Wire)
Sep-02-25 07:00AM	IFF Tackles Top Challenges in Baking at IBIE 2025 (Business Wire)
Aug-27-25 04:00AM	IFF and Reservas Votorantim Sign Bioprospecting Partnership in Brazil (Business Wire)
Aug-19-25 08:05AM	What Are Wall Street Analysts' Target Price for International Flavors & Fragrances Stock? (Barchart)
Aug-15-25 12:02PM	IFF Launches POWERFRESH ACE 2000 to Enhance Bread Sustainability (Zacks)
Aug-13-25 04:15PM	IFF to Webcast Fireside Chat at Barclays Global Consumer Staples Conference on Sept. 4 (Business Wire)
07:00AM	IFF Launches POWERFRESH ACE 2000, a Bread Fresh-Keeping Solution That Aces the Shelf-Life Test (Business Wire)
Aug-11-25 09:15AM	International Flavors (IFF) Reliance on International Sales: What Investors Need to Know (Zacks)
Aug-07-25 04:30AM	[Latest] Global Antioxidant BHT Market Size/Share Worth USD 542 Million by 2034 at a 6.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-06-25 12:55PM	International Flavors Q2 Earnings Beat Estimates, Sales Dip Y/Y (Zacks)
11:02AM	Analyst Report: International Flavors & Fragrances Inc. (Morningstar Research)
Aug-05-25 06:00PM	International Flavors (IFF) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	International Flavors (IFF) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:26PM	International Flavors: Q2 Earnings Snapshot (Associated Press Finance)

International Flavors & Fragrances, Inc. engages in the manufacture and supply of flavors and fragrances used in the food, beverage, personal care, and household products industries. It operates through the following segments: Nourish, Health & Biosciences, Scent and Pharma Solutions. The Nourish segment consists of legacy Taste segment combined with N&B's Food & Beverage division and the food protection business of N&B's Health & Biosciences division. The Health & Biosciences business consists of a biotechnology-driven portfolio of enzymes, food cultures, probiotics and specialty ingredients for food, home and personal care, and health and wellness applications. The Scent business creates fragrance compounds, fragrance ingredients and cosmetic ingredients that are integral elements in the world's finest perfumes and best-known household and personal care products. The Pharma Solutions business produces a vast portfolio including cellulosics and seaweed-based pharma excipients, used to improve the functionality and delivery of active pharmaceutical ingredients, including controlled or modified drug release formulations, and enabling. The company was founded in 1833 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FRIBOURG PAUL J	Director	Mar 12 '26	Buy	70.13	142,000	9,957,963	2,422,730	Mar 16 04:33 PM
FRIBOURG PAUL J	Director	Mar 12 '26	Buy	70.07	14,200	995,015	29,650	Mar 16 04:33 PM
FRIBOURG PAUL J	Director	Feb 09 '26	Buy	74.63	146	10,896	409	Mar 16 04:33 PM
FRIBOURG PAUL J	Director	Aug 27 '25	Buy	66.91	71	4,751	450	Mar 16 04:33 PM
FRIBOURG PAUL J	Director	Oct 30 '25	Buy	63.64	39	2,482	39	Mar 16 04:33 PM
FRIBOURG PAUL J	Director	Mar 06 '26	Buy	73.93	3	222	11	Mar 16 04:33 PM
FRIBOURG PAUL J	Director	Nov 18 '25	Sale	65.42	187	12,234	263	Mar 16 04:33 PM
FRIBOURG PAUL J	Director	Dec 10 '25	Sale	65.27	25	1,632	11	Mar 16 04:33 PM
FRIBOURG PAUL J	Director	Sep 29 '25	Sale	60.87	7	426	0	Mar 16 04:33 PM
FRIBOURG PAUL J	Director	Dec 15 '25	Sale	63.35	3	190	8	Mar 16 04:33 PM
Fyrwald J Erik	Chief Executive Officer	Mar 13 '26	Buy	69.85	13,360	933,224	91,630	Mar 16 04:33 PM
Fyrwald J Erik	Chief Executive Officer	Mar 12 '26	Buy	68.87	900	61,980	78,270	Mar 16 04:33 PM
Muller Andres Roberto	President, Food Ingredients	Jan 02 '26	Option Exercise	0.00	1,825	0	1,825	Jan 05 05:33 PM
Landsman Stephen N	EVP, General Counsel	Dec 12 '25	Buy	63.48	3,100	196,788	15,100	Dec 12 04:18 PM
Finzel Ralf	EVP, Global Operations Officer	Dec 01 '25	Option Exercise	0.00	10,774	0	20,073	Dec 02 04:20 PM
Yildiz Beril	Former Officer	Nov 07 '25	Proposed Sale	62.51	4,060	253,810		Nov 07 01:28 PM
Borg Deborah	EVP, Chief Ppl&Culture Officer	Sep 02 '25	Option Exercise	0.00	13,808	0	41,288	Sep 03 06:16 PM
FRIBOURG PAUL J	Director	Aug 07 '25	Buy	64.80	15,450	1,001,183	15,450	Aug 08 06:49 PM
Fyrwald J Erik	Chief Executive Officer	Aug 07 '25	Buy	64.95	15,300	993,714	77,370	Aug 07 06:59 PM
Teles de Mendonca Ana Paula	President, Scent	Jun 02 '25	Option Exercise	0.00	643	0	3,088	Jun 04 05:38 PM
Arora Yuvraj	President, Taste & CCO	May 05 '25	Option Exercise	0.00	17,309	0	22,291	Jun 04 05:27 PM
Arora Yuvraj	President, Taste & CCO	May 01 '25	Option Exercise	0.00	3,572	0	6,810	Jun 04 05:27 PM
O'Byrne Kevin	Director	May 22 '25	Buy	76.05	4,500	342,240	7,696	May 23 04:46 PM
Teles de Mendonca Ana Paula	President, Scent	May 05 '25	Option Exercise	0.00	1,498	0	3,210	May 22 07:30 PM
Teles de Mendonca Ana Paula	President, Scent	May 01 '25	Option Exercise	0.00	1,587	0	2,523	May 22 07:30 PM
Palau Hernandez Margarita	Director	May 19 '25	Buy	77.42	850	65,807	2,393	May 20 01:33 PM
Yildiz Beril	CAO, SVP & Controller	May 19 '25	Sale	77.33	2,400	185,604	3,321	May 19 05:09 PM
Landsman Stephen N	EVP, General Counsel	May 19 '25	Buy	77.28	12,000	927,356	12,000	May 19 05:08 PM
Yildiz Beril	Officer	May 19 '25	Proposed Sale	77.33	2,400	185,604		May 19 01:12 PM
Yildiz Beril	CAO, SVP & Controller	May 05 '25	Option Exercise	0.00	849	0	6,028	May 16 09:01 PM
Yildiz Beril	CAO, SVP & Controller	May 01 '25	Option Exercise	0.00	952	0	5,523	May 16 09:01 PM
Finzel Ralf	EVP, Global Operations Officer	May 05 '25	Option Exercise	0.00	1,326	0	9,976	May 16 09:01 PM
Finzel Ralf	EVP, Global Operations Officer	May 01 '25	Option Exercise	0.00	1,984	0	9,663	May 16 09:01 PM
DeVeau Michael	EVP, CFO	May 05 '25	Option Exercise	0.00	884	0	11,048	May 16 09:01 PM
DeVeau Michael	EVP, CFO	May 01 '25	Option Exercise	0.00	1,389	0	10,874	May 16 09:01 PM
Borg Deborah	EVP, Chief Ppl&Culture Officer	May 05 '25	Option Exercise	0.00	1,768	0	28,383	May 16 09:00 PM
Borg Deborah	EVP, Chief Ppl&Culture Officer	May 01 '25	Option Exercise	0.00	2,381	0	27,817	May 16 09:00 PM
Palau Hernandez Margarita	Director	May 01 '25	Option Exercise	0.00	1,543	0	1,543	May 16 08:57 PM
O'Byrne Kevin	Director	May 01 '25	Option Exercise	0.00	1,875	0	3,590	May 16 08:56 PM
Khan Mehmood	Director	May 15 '25	Buy	75.33	4,000	301,314	4,604	May 15 05:27 PM
Fyrwald J Erik	Chief Executive Officer	May 09 '25	Buy	73.97	24,300	1,797,456	62,070	May 09 05:03 PM
Fyrwald J Erik	Chief Executive Officer	May 08 '25	Buy	74.00	700	51,797	37,770	May 09 05:03 PM
JAMISON CYNTHIA T	Director	May 01 '25	Option Exercise	0.00	604	0	604	May 05 05:51 PM
INTRIERI VINCENT J	Director	May 01 '25	Option Exercise	0.00	604	0	604	May 05 05:50 PM
Costa Mark J	Director	May 01 '25	Option Exercise	0.00	1,875	0	4,014	May 05 05:50 PM
Khan Mehmood	Director	May 01 '25	Option Exercise	0.00	604	0	604	May 05 05:47 PM
Fyrwald J Erik	Chief Executive Officer	May 01 '25	Option Exercise	0.00	15,875	0	45,175	May 05 05:46 PM
Strzelecki Angela	President, Pharma Solutions	Apr 04 '25	Option Exercise	0.00	1,761	0	10,362	Apr 07 04:17 PM
DeVeau Michael	CFO	Apr 04 '25	Option Exercise	0.00	1,993	0	10,204	Apr 07 04:16 PM
Borg Deborah	EVP, Chief Ppl&Culture Officer	Apr 04 '25	Option Exercise	0.00	4,602	0	27,981	Apr 07 04:16 PM

Open in Screener

LLY

Lilly(Eli) & Co

Mar 27 • 04:00PM ET

878.24

-18.76 -2.09 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: NVO JNJ ABBV MRK AZN-D AMGN PFE SNY BMY GSK

| Held by: VTI VOO VUG IVV SPY XLV VIG IWF VHT IVW

Index	S&P 500	P/E	38.88	EPS (ttm)	22.59	Insider Own	9.96%	Shs Outstand	944.80M	Perf Week	-3.14%
Market Cap	829.78B	Forward P/E	20.90	EPS next Y	42.02	Insider Trans	-3.79%	Shs Float	850.75M	Perf Month	-14.07%
Enterprise Value	866.37B	PEG	0.78	EPS next Q	7.26	Inst Own	74.27%	Short Float	0.81%	Perf Quarter	-18.45%
Income	20.64B	P/S	12.73	EPS this Y	42.21%	Inst Trans	1.13%	Short Ratio	2.22	Perf Half Y	22.90%
Sales	65.18B	P/B	31.27	EPS next Y	22.04%	ROA	21.59%	Short Interest	6.87M	Perf YTD	-18.28%
Book/sh	28.09	P/C	114.17	EPS next 5Y	26.67%	ROE	101.35%	52W High	1133.95 -22.55%	Perf Year	6.88%
Cash/sh	7.69	P/FCF	92.49	EPS past 3/5Y	49.25% 27.59%	ROIC	30.11%	52W Low	623.78 40.79%	Perf 3Y	162.47%
Dividend Est.	7.02 (0.80%)	EV/EBITDA	27.34	Sales past 3/5Y	31.69% 21.58%	Gross Margin	83.04%	Volatility	2.00% 2.58%	Perf 5Y	373.93%
Dividend TTM	6.23 (0.71%)	EV/Sales	13.29	EPS Y/Y TTM	96.48%	Oper. Margin	45.56%	ATR (14)	26.99	Perf 10Y	1134.87%
Dividend Ex-Date	Feb 13, 2026	Quick Ratio	1.19	Sales Y/Y TTM	44.70%	Profit Margin	31.66%	RSI (14)	29.13	Recom	1.49
Dividend Gr. 3/5Y	15.24% 15.18%	Current Ratio	1.58	EPS Q/Q	50.92%	SMA20	-8.24%	Beta	0.52	Target Price	1240.21
Payout	26.14%	Debt/Eq	1.65	Sales Q/Q	42.56%	SMA50	-12.81%	Rel Volume	0.88	Prev Close	897.00
Employees	50000	LT Debt/Eq	1.58	Earnings	Feb 04 BMO	SMA200	-1.95%	Avg Volume	3.10M	Price	878.24
IPO	Jul 09, 1970	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.10% 7.51%	Trades		Volume	2,735,169	Change	-2.09%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-26	Downgrade	HSBC Securities	Hold → Reduce	$850
Feb-25-26	Initiated	RBC Capital Mkts	Outperform	$1250
Feb-20-26	Initiated	Barclays	Overweight	$1350
Jan-07-26	Resumed	UBS	Buy	$1250
Dec-16-25	Upgrade	Daiwa Securities	Neutral → Buy	$1230
Dec-15-25	Reiterated	Goldman	Buy	$951 → $1145
Dec-15-25	Reiterated	BofA Securities	Buy	$1286 → $1268
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$1165
Nov-10-25	Upgrade	Leerink Partners	Market Perform → Outperform	$1104
Oct-20-25	Reiterated	BMO Capital Markets	Outperform	$840 → $930
Oct-14-25	Upgrade	Erste Group	Hold → Buy
Sep-17-25	Downgrade	Berenberg	Buy → Hold	$830
Aug-27-25	Upgrade	HSBC Securities	Reduce → Hold	$700
Aug-18-25	Downgrade	Daiwa Securities	Outperform → Neutral	$700
Aug-07-25	Downgrade	Leerink Partners	Outperform → Market Perform	$715
Jun-05-25	Downgrade	Erste Group	Buy → Hold
Apr-28-25	Downgrade	HSBC Securities	Buy → Reduce	$1150 → $700
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$975
Dec-10-24	Resumed	BofA Securities	Buy	$997
Nov-15-24	Initiated	Wolfe Research	Outperform	$1000

Show Previous Ratings

Mar-28-26 03:15PM	Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity (PR Newswire)
Mar-27-26 05:54PM	Why you should 'never count out' Google (Yahoo Finance Video)
09:00AM	Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis (PR Newswire)
Mar-26-26 09:40AM	Wave Plunges More Than 50% After Obesity Shot Falls Short (Bloomberg)
08:30AM	Novo Nordisk GLP-1 pipeline shows promise but oral drug trends give analysts pause (Proactive)
08:15AM	Loading…
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
Mar-21-26 03:45AM	Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment (Investing.com)
Mar-20-26 05:19PM	Big drugmakers saved at least $5bn on US taxes shifting income overseas (Financial Times)
05:13PM	Market Madness: Palantir, Walmart, & other hot stock picks (Yahoo Finance Video)
12:48PM	Eli Lilly's experimental diabetes drug helped patients lose 17% of their body weight (Quartz)
09:24AM	Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat' (Investor's Business Daily)
07:12AM	Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern (Proactive)
04:00AM	Lillys manufacturing bet; hints of a biotech revival (Pharma Voice)
Mar-19-26 03:49PM	Novo Tries New Japan Strategy To Boost Demand (GuruFocus.com)
02:42PM	A high dose of Wegovy helped people lose 21% of their weight. It was just approved. (MarketWatch)
11:37AM	Loading…
11:37AM	Eli Lillys next-generation obesity drug delivers strong results in late-stage trial (Proactive)
09:56AM	Eli Lilly's experimental diabetes drug cuts weight by 17% in study (Quartz)
08:50AM	Eli Lilly's 'Triple Agonist' Is More Than Just a Weight-Loss Drug. This Trial Proves It. (Barrons.com)
07:32AM	Lilly's Retatrutide Slashes Both Weight Loss and Blood Sugar Levels (The Wall Street Journal)
07:19AM	Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage Trial (Investor's Business Daily)
06:45AM	Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes (PR Newswire)
Mar-18-26 02:29PM	Analysis-TrumpRx lists many medicines at prices higher than paid in UK (Reuters)
01:39PM	Healthcare Stocks Are Trading at a Deep Discount. Eli Lilly and Others Are Worth a Look. (Barrons.com)
11:42AM	It's time to rethink how we define obesity as millions turn to GLP-1s (MarketWatch)
Mar-17-26 04:36PM	Stock Indexes Advance as Chip Makers and Travel Stocks Rally (Barchart)
04:21PM	HSBC Downgrades Eli Lilly, Cuts PT to $850, Flags Obesity Market Risks (GuruFocus.com)
02:49PM	Stocks trade near session lows in afternoon action, as Eli Lilly weighs on the S&P 500 (MarketWatch)
02:28PM	Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound's cash sales (MarketWatch)
02:19PM	Eli Lilly Stock Gets Downgraded. It Faces Stiff Headwinds After Strong Run-Up. (Barrons.com)
02:09PM	These Stocks Are Today's Movers: Nvidia, Eli Lilly, Oklo, Swarmer, Delta, Semtech, Uber, and More (Barrons.com)
11:17AM	Loading…
11:17AM	Stocks Climb on Strength in Chip and Travel Stocks (Barchart)
10:21AM	Eli Lilly Stock Downgraded on Inflated Obesity Drug Market (Schaeffer's Research)
10:15AM	Stocks Supported by Lower Bond Yields (Barchart)
10:00AM	HSBC downgrades Eli Lilly, says shares are priced to perfection (Investing.com)
09:33AM	DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls (The Fly)
06:35AM	Stock Index Futures Muted as Oil Prices Resume Advance After Iran Strikes, FOMC Meeting in Focus (Barchart)
Mar-16-26 07:35AM	Structures GLP-1 pill shows best-in-class potential in obesity trial (BioPharma Dive)
06:45AM	Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis (PR Newswire)
Mar-13-26 04:00AM	Novo regained weight loss footing in the pill arena but Lilly is coming (Pharma Voice)
04:00AM	Keytrudas reign continues; pharmas megadeal drought (Pharma Voice)
Mar-12-26 04:51PM	Why Investors Aren't Fleeing to Safe-Haven Stocks (The Wall Street Journal)
03:21PM	Eli Lilly Warns Tirzepatide-B12 Mix in Compounded Drugs May Pose Safety Risks (GuruFocus.com)
02:48PM	Eli Lilly Stock Slips After Warning on Compounded GLP-1 Drugs With Additives (GuruFocus.com)
02:17PM	Lilly Flags Safety Risk In Compounded GLP 1 (GuruFocus.com)
10:57AM	Should You Chase the Rally in Hims & Hers Stock Today? (Barchart)
07:40AM	Lilly warns GLP-1 knockoffs may be dangerous, escalating war with compounders (BioPharma Dive)
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-11-26 04:37PM	Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50 (GuruFocus.com)
02:28PM	Hims & Hers Hires Ex-Eli Lilly Communications Chief Amid Obesity Drug Strategy Shift (GuruFocus.com)
02:25PM	Hims & Hers C-suite shake-up, Stryker outage may be Iran-backed (Yahoo Finance Video)
02:14PM	Eli Lilly Stock In Spotlight -- Announces $3 Billion Investment Plan in China (GuruFocus.com)
12:38PM	Hims & Hers Brings In Lilly Communications Veteran (GuruFocus.com)
11:31AM	Eli Lilly to invest $3bn in China in anticipation of orforglipron approval (Pharmaceutical Technology)
10:07AM	Wolfe bumps Eli Lilly target on oral obesity drug, cardiometabolic portfolio (Investing.com)
09:00AM	Lilly Flags A Catch In $50 GLP-1 Plan (GuruFocus.com)
07:30AM	Lilly unveils $3 billion production expansion in China (BioPharma Dive)
Mar-10-26 03:36PM	Cathie Wood, Senator Markwayne Mullin Align On These 7 Stock Picks - Some Might Surprise You (Benzinga)
02:39PM	Eli Lilly Says Some Medicare GLP-1 Patients May Pay Above $50 Under New CMS Model (GuruFocus.com)
08:21AM	Novo Nordisk downgraded as pipeline not poised to blunt semaglutide LOE (Investing.com)
07:34AM	Eli Lilly and Company (LLY) Set to Launch Oral Obesity Drug in Q2, Reuters Reports (Insider Monkey)
05:45AM	Eli Lilly and Company (LLY) Announces the Launch of its Employer Connect Platform (Insider Monkey)
12:01AM	Hims Teams up with Novo to Compete for Weight Loss Scripts (The Daily Upside)
Mar-09-26 05:45PM	Eli Lilly (LLY) Laps the Stock Market: Here's Why (Zacks)
01:42PM	Factbox-Global drugmakers rush to boost US presence as tariff threat looms (Reuters)
12:46PM	Amazon Pharmacy Brings Zepbound's New KwikPen (GuruFocus.com)
12:15PM	Hims & Hers Stock Soars. Its Weight-Loss Drug Battle With Novo Nordisk Takes a Surprising Twist. (Barrons.com)
10:35AM	HIMS Stock Eyes Best Day Ever After Dispute Dissolution (Schaeffer's Research)
09:34AM	Hims And Hers Surges 40% On Deal To Sell Novo Nordisk Obesity Drugs (Investor's Business Daily)
09:05AM	NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell? (Zacks)
08:19AM	Roches prized breast cancer pill fails closely watched study (BioPharma Dive)
08:09AM	Roche's Breast Cancer Drug Falls Short In Phase 3 Study (Benzinga)
07:00AM	Hims And Hers Surges Over 50% On Deal To Sell Novo Nordisk Obesity Drugs (Investor's Business Daily)
04:21AM	Zacks Market Edge Highlights: Caterpillar, Eli Lilly and Comfort Systems (Zacks)
Mar-07-26 10:56AM	Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce (24/7 Wall St.)
Mar-06-26 09:52PM	Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report (Benzinga)
03:48PM	Jobs Report Just Dented Most Bulletproof Sector ETF In The Market (Benzinga)
01:11PM	3 Stocks for Your Wish List (Zacks)
11:30AM	Lilly (LLY) Down 3.7% Since Last Earnings Report: Can It Rebound? (Zacks)
11:28AM	Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal (Zacks)
08:41AM	Zealand Pharma CEO Says Most-Tolerable Drugs Will Be Next to Win in Obesity Market (The Wall Street Journal)
08:19AM	Eli Lilly (LLY) Edged Higher as Multiple Tailwinds Aligned (Insider Monkey)
06:47AM	Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk And Eli Lilly (Benzinga)
04:20AM	Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial (The Wall Street Journal)
Mar-05-26 04:23PM	Stock Market Today: Nasdaq Cuts Losses As Dow Still Falls Nearly 800 Points; Eli Lilly Hits Sell Signal (Live Coverage) (Investor's Business Daily)
03:48PM	Stock Market Today: Dow, Banks Fall Hard, Ciena Slammed; Eli Lilly Hits Sell Signal (Live Coverage) (Investor's Business Daily)
03:07PM	Stock Market Today: Dow Plunges 1,100 Points; Ciena Sinks As Eli Lilly Marks Sell Signal (Live Coverage) (Investor's Business Daily)
08:12AM	Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? (Zacks)
06:47AM	Lilly targets employers in new bid to broaden access to obesity drugs (BioPharma Dive)
06:00AM	Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients (PR Newswire)
Mar-04-26 03:30PM	Forget AI. This Biotech Stocks Taking Off Right Now (24/7 Wall St.)
12:18PM	Hims & Hers Slips as FDA Targets GLP-1 Compounders (GuruFocus.com)
09:50AM	Here's Why Eli Lilly (LLY) is a Strong Momentum Stock (Zacks)
07:49AM	Is Moderna Stock Outperforming the Dow? (Barchart)
Mar-03-26 08:02PM	Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference (MarketBeat)
09:10AM	Immunology, Neuroscience Step Up as Key Growth Engines for J&J (Zacks)
09:00AM	Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know (Zacks)
09:00AM	Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion (PR Newswire)
04:46AM	Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer (Zacks)
Mar-02-26 03:29PM	Barclays names 2 drug stocks investors should own in 2026 (TheStreet)
01:37PM	Tech giants see a cure for cancer in AI. But Eli Lillys CEO finds it not particularly good at solving biology or chemistry problems (Fortune)

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zakrowski Donald A	SVP, Finance, & CAO	Feb 16 '26	Option Exercise	0.00	184	0	3,607	Feb 18 04:22 PM
Montarce Lucas	EVP & CFO	Feb 16 '26	Option Exercise	0.00	368	0	16,418	Feb 18 04:21 PM
Custer Kenneth L.	EVP & President, Card Met Hlth	Feb 16 '26	Option Exercise	0.00	207	0	10,232	Feb 18 04:21 PM
Brown Adrienne S	EVP, President LLY Imm	Feb 16 '26	Option Exercise	0.00	391	0	5,312	Feb 18 04:19 PM
Yuffa Ilya	EVP&Pres, LLY USA&Global Capab	Feb 01 '26	Option Exercise	0.00	3,394	0	29,654	Feb 03 04:32 PM
Skovronsky Daniel	EVP, CS&PO & Pres. LRL	Feb 01 '26	Option Exercise	0.00	12,684	0	150,165	Feb 03 04:31 PM
Van Naarden Jacob	EVP,Pres LLY Oncology&HdCorpBD	Feb 01 '26	Option Exercise	0.00	4,108	0	24,670	Feb 03 04:31 PM
Ricks David A	President, Chair, and CEO	Feb 01 '26	Option Exercise	0.00	31,932	0	547,098	Feb 03 04:29 PM
Rau Diogo	EVP & CIDO	Feb 01 '26	Option Exercise	0.00	3,752	0	23,471	Feb 03 04:28 PM
Jonsson Patrik	EVP & President, LLY Int'l	Feb 01 '26	Option Exercise	0.00	3,930	0	57,581	Feb 03 04:27 PM
Hernandez Edgardo	EVP & Pres., Mfg. Operations	Feb 01 '26	Option Exercise	0.00	3,572	0	43,303	Feb 03 04:26 PM
Hakim Anat	EVP, GC & Secretary	Feb 01 '26	Option Exercise	0.00	6,700	0	17,662	Feb 03 04:25 PM
Dozier Eric	EVP, Chief People Officer	Feb 01 '26	Option Exercise	0.00	2,858	0	12,697	Feb 03 04:24 PM
LILLY ENDOWMENT INC	10% Owner	Jan 07 '26	Sale	1103.48	292,148	322,380,730	91,896,978	Jan 08 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jan 05 '26	Sale	1085.01	1,390	1,508,165	92,189,126	Jan 06 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Dec 29 '25	Sale	1085.04	3,593	3,898,531	92,190,516	Dec 30 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Dec 24 '25	Sale	1085.17	2,629	2,852,920	92,194,109	Dec 29 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Dec 23 '25	Sale	1085.04	240	260,409	92,196,738	Dec 29 04:00 PM
LILLY ENDOWMENT, INC.	10% Owner	Dec 23 '25	Proposed Sale	1076.48	300,000	322,944,000		Dec 23 12:52 PM
LILLY ENDOWMENT INC	10% Owner	Nov 25 '25	Sale	1109.30	15,632	17,340,625	92,196,978	Nov 26 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 25 '25	Sale	1095.35	147,061	161,082,640	92,212,610	Nov 26 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 24 '25	Sale	1068.52	142,307	152,058,091	92,359,671	Nov 25 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 21 '25	Sale	1058.66	105,326	111,504,098	92,501,978	Nov 24 04:00 PM
LILLY ENDOWMENT, INC.	10% Owner	Nov 24 '25	Proposed Sale	1059.70	305,000	323,208,500		Nov 24 03:01 PM
LILLY ENDOWMENT INC	10% Owner	Nov 20 '25	Sale	1051.66	37,148	39,067,117	92,607,304	Nov 21 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 19 '25	Sale	1051.17	167,526	176,098,702	92,644,452	Nov 20 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 18 '25	Sale	1034.78	60,213	62,306,969	92,811,978	Nov 19 04:00 PM
LILLY ENDOWMENT, INC.	10% Owner	Nov 19 '25	Proposed Sale	1030.05	310,000	319,315,500		Nov 19 03:05 PM
LILLY ENDOWMENT INC	10% Owner	Nov 17 '25	Sale	1030.68	9,886	10,189,269	92,872,191	Nov 18 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 14 '25	Sale	1030.87	178,295	183,799,044	92,882,077	Nov 17 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 13 '25	Sale	1030.26	46,606	48,016,098	93,060,372	Nov 14 04:00 PM
Zakrowski Donald A	SVP, Finance, & CAO	Nov 13 '25	Sale	1010.50	1,000	1,010,500	2,840	Nov 13 04:14 PM
LILLY ENDOWMENT INC	10% Owner	Nov 12 '25	Sale	1011.18	305,000	308,411,204	93,106,978	Nov 13 04:00 PM
LILLY ENDOWMENT, INC.	10% Owner	Nov 13 '25	Proposed Sale	1017.78	295,000	300,245,100		Nov 13 03:02 PM
LILLY ENDOWMENT INC	10% Owner	Nov 11 '25	Sale	986.64	283,131	279,347,680	93,411,978	Nov 12 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 10 '25	Sale	972.52	16,869	16,405,396	93,695,109	Nov 12 04:00 PM
LILLY ENDOWMENT, INC.	10% Owner	Nov 12 '25	Proposed Sale	988.62	305,000	301,529,100		Nov 12 03:15 PM
LILLY ENDOWMENT, INC.	10% Owner	Nov 10 '25	Proposed Sale	924.37	300,000	277,311,000		Nov 10 03:11 PM
LILLY ENDOWMENT INC	10% Owner	Nov 05 '25	Sale	951.56	40,432	38,473,442	93,711,978	Nov 06 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 05 '25	Sale	933.26	179,042	167,092,104	93,752,410	Nov 06 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 04 '25	Sale	910.72	526	479,038	93,931,452	Nov 05 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Nov 03 '25	Sale	888.83	300,000	266,648,921	93,931,978	Nov 04 04:00 PM
LILLY ENDOWMENT, INC.	10% Owner	Nov 04 '25	Proposed Sale	896.53	220,000	197,236,600		Nov 04 03:05 PM
LILLY ENDOWMENT INC	10% Owner	Oct 31 '25	Sale	863.35	301,342	260,165,031	94,231,978	Nov 03 04:00 PM
LILLY ENDOWMENT, INC.	10% Owner	Nov 03 '25	Proposed Sale	862.86	300,000	258,858,000		Nov 03 03:06 PM
LILLY ENDOWMENT INC	10% Owner	Oct 10 '25	Sale	863.24	3,658	3,157,722	94,533,320	Oct 14 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Oct 09 '25	Sale	852.49	10,602	9,038,055	94,536,978	Oct 10 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Oct 10 '25	Proposed Sale	855.35	305,000	260,881,750		Oct 10 02:57 PM
LILLY ENDOWMENT INC	10% Owner	Oct 08 '25	Sale	850.27	101,420	86,234,874	94,547,580	Oct 09 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Oct 07 '25	Sale	848.01	26,795	22,722,401	94,649,000	Oct 08 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Oct 06 '25	Sale	850.22	161,183	137,041,657	94,675,795	Oct 07 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Oct 03 '25	Sale	837.93	192,404	161,220,401	94,836,978	Oct 06 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Oct 06 '25	Proposed Sale	839.87	300,000	251,961,000		Oct 06 03:35 PM
LILLY ENDOWMENT INC	10% Owner	Oct 02 '25	Sale	821.55	112,596	92,503,361	95,029,382	Oct 03 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Oct 01 '25	Sale	821.47	215,822	177,290,448	95,141,978	Oct 02 04:56 PM
LILLY ENDOWMENT INC	10% Owner	Oct 01 '25	Sale	794.15	135,193	107,363,016	95,357,800	Oct 02 04:55 PM
LILLY ENDOWMENT INC	10% Owner	Oct 02 '25	Proposed Sale	825.42	305,000	251,753,100		Oct 02 03:20 PM
LILLY ENDOWMENT INC	10% Owner	Oct 01 '25	Proposed Sale	763.00	295,000	225,085,000		Oct 01 04:08 PM
LILLY ENDOWMENT INC	10% Owner	Sep 30 '25	Sale	763.39	113,694	86,793,274	95,492,993	Oct 01 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Sep 19 '25	Sale	763.10	23,665	18,058,643	95,606,687	Sep 22 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Sep 18 '25	Sale	764.65	106,626	81,531,959	95,630,352	Sep 19 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Sep 18 '25	Proposed Sale	760.13	300,000	228,039,000		Sep 18 03:04 PM
DONALD ZAKROWSKI	Officer	Aug 28 '25	Proposed Sale	734.17	2,000	1,468,340		Aug 28 04:19 PM
Zakrowski Donald A	SVP, Finance, & CAO	Aug 28 '25	Sale	734.93	1,000	734,930	3,840	Aug 28 04:14 PM
Montarce Lucas	EVP & CFO	Aug 15 '25	Buy	691.79	715	494,627	14,685	Aug 15 04:13 PM
Alvarez Ralph	Director	Aug 13 '25	Buy	660.25	758	500,473	758	Aug 14 04:12 PM
Van Naarden Jacob	EVP & Pres., Lilly Oncology	Aug 13 '25	Buy	647.36	1,000	647,360	20,562	Aug 13 04:15 PM
Ricks David A	President, Chair, and CEO	Aug 12 '25	Buy	644.77	1,632	1,052,263	546,601	Aug 12 04:23 PM
Skovronsky Daniel	EVP, CSO & Pres. LRL & LLY Imm	Aug 12 '25	Buy	634.40	1,000	634,405	137,660	Aug 12 04:20 PM
Sulzberger Gabrielle	Director	Aug 12 '25	Buy	641.18	117	75,018	2,703	Aug 12 04:19 PM
Fyrwald J Erik	Director	Aug 12 '25	Buy	642.33	1,565	1,005,242	74,578	Aug 12 04:17 PM
Yuffa Ilya	EVP&Pres, LLY USA&Global Capab	Aug 11 '25	Sale	627.01	1,250	783,762	26,260	Aug 12 04:16 PM
JACKSON JAMERE	Director	Aug 08 '25	Buy	639.56	200	127,913	9,402	Aug 08 04:20 PM
Seymour Melissa	EVP, Global Quality	Aug 01 '25	Option Exercise	0.00	952	0	952	Aug 04 04:16 PM
LILLY ENDOWMENT INC	10% Owner	Jul 24 '25	Sale	805.07	280,000	225,419,259	95,736,978	Jul 25 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jul 24 '25	Proposed Sale	798.89	280,000	223,689,200		Jul 24 03:01 PM
Zakrowski Donald A	SVP, Finance, & CAO	May 27 '25	Sale	716.41	1,000	716,410	4,840	May 27 04:13 PM
Yuffa Ilya	EVP & President, LLY Int'l	May 14 '25	Sale	749.24	1,250	936,550	27,510	May 15 04:17 PM
Yuffa Ilya	Officer	May 14 '25	Proposed Sale	749.24	2,500	1,873,100		May 14 12:25 PM

IFF

International Flavors & Fragrances Inc

LLY

Lilly(Eli) & Co

Upgrade your FINVIZ experience